4BIO Capital
24+Portfolio
4BIO Capital is a London‑based venture fund that invests exclusively in advanced therapy companies developing cell, gene, RNA‑based, targeted and microbiome treatments for high unmet medical needs. The firm focuses on early‑stage opportunities where scientific innovation can translate into curative or transformative therapies, leveraging its deep expertise and network in life sciences. By providing capital and strategic guidance, 4BIO aims to accelerate the path to market for breakthrough treatments that address critical health challenges.
Where they invest
Geography
Portfolio footprintHover a country to explore
- United States of America
- 36.4%
- United Kingdom
- 27.3%
- Italy
- 9.1%
- France
- 9.1%
Darker countries represent a larger share of the portfolio.
What they back
Industries
- Biotechnology
- 81.8%
- Financial Technology
- 18.2%
- Drug Discovery & Therapeutics
- 9.1%
- Healthcare Technology
- 9.1%
- Clean Technology
- 9.1%
- Energy
- 9.1%
% of all portfolio companies. Industry categories can overlap.
Stages
Stage indicator
Pre-Seed → Series A
Fund details
Funds
4BIO Ventures III LP
Vintage 2023 • $153.9
4BIO Ventures II LP
Vintage 2021 • $109.6
4BIO Advanced Therapies Fund ICAV
Vintage 2021 • $0.4
4BIO Advanced Therapies Long Equity Fund
Vintage 2021 • $0.4
4BIO Advanced Therapies Fund
Vintage 2019 • $49.5